Skip to main content
Equibles
CSBR logo

CSBR · Champions Oncology, Inc. · Metrics

Track CSBR — free

Use CSBR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CSBR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.83 +0.00 (+0.00%) Q3 2026 earnings call transcript
Rebalance outlook locked
Market Cap
$67.23M
Shares
13.92M
Volume · Oct 28 2759 Avg daily vol (3M) 11.13K

CSBR metrics

95 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.83
Market cap
$67.23M

Price action

20 metrics
Price change (1W)
+0.4%
Price change (30D)
-2.0%
Price change (3M)
-12.7%
Price change (6M)
-18.3%
Price change (YTD)
-30.1%
Price change (1Y)
-29.2%
Trailing year
Price change (5Y)
-50.5%
52-week high
$7.80
52-week low
$4.69
Change from 52-week high
-38.1%
Change from 52-week low
+3.0%
Annualized volatility
53.5%
Annualized volatility (3M)
43.4%
Beta
0.5
RSI (14D)
47.4
Price vs SMA 50
-2.7%
Price vs SMA 200
-16.4%
Avg volume (3M)
11,129
Relative volume
0.3
Average dollar volume
$56,310

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
13.92M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.1×
reciprocal yield 90.2%
P / book
17.3
reciprocal yield 5.8%
FCF yield
-9.1%
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-1.6%

Historical valuation

8 metrics
P / E historical average (3Y)
32.4×
reciprocal yield 3.1%
P / E historical average (5Y)
221.9×
reciprocal yield 0.5%
EV / revenue historical average (3Y)
2.0×
reciprocal yield 50.2%
EV / revenue historical average (5Y)
2.2×
reciprocal yield 46.2%
EV / EBIT historical average (3Y)
379.2×
reciprocal yield 0.3%
EV / EBIT historical average (5Y)
379.2×
reciprocal yield 0.3%
EV / EBITDA historical average (3Y)
59.1×
reciprocal yield 1.7%
EV / EBITDA historical average (5Y)
59.1×
reciprocal yield 1.7%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-09-10

Profitability

9 metrics
Gross margin
49.8%
Operating margin
-1.7%
Trailing 12 months
Net margin
-1.8%
Gross profit (TTM)
$30.22M
Operating profit (TTM)
−$1.02M
Net income (TTM)
−$1.10M
Trailing 12 months
Diluted EPS (TTM)
$-0.08
FCF margin
-10.1%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$4.30
Gross profit per diluted share (TTM)
$2.06
Operating profit per diluted share (TTM)
$-0.08
EBITDA per diluted share (TTM)
$0.02
Net income per diluted share (TTM)
$-0.09
Operating cash flow per diluted share (TTM)
$-0.32
Free cash flow per diluted share (TTM)
$-0.37
Capital expenditures per diluted share (TTM)
$0.04
R&D per diluted share (TTM)
$0.66
Stock compensation per diluted share (TTM)
$0.09
Book value per share
$0.28

Growth

11 metrics
Revenue growth YoY
+8.8%
Year over year
Net income growth YoY
-125.0%
Revenue (TTM)
$60.66M
Trailing 12 months
EPS growth YoY
-124.2%
Shares change YoY
-3.3%
Year over year · fewer shares
Revenue CAGR (3Y)
+3.3%
Revenue CAGR (5Y)
+7.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-28.4%
Return on assets
-3.3%
Debt / equity
—
Current ratio
1.0
EBITDA (TTM)
$334,000
Free cash flow (TTM)
−$6.14M
Quick ratio
1.0
Interest coverage
—
Net debt / EBITDA
-13.0
Return on invested capital
—
Trailing 12 months
Net cash
$4.36M
Latest balance sheet
Cash & equivalents
$4.36M
Total assets
$33.29M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$5.56M
Capital expenditures (TTM)
$573,000
R&D (TTM)
$9.35M
SG&A (TTM)
—
Stock compensation (TTM)
$1.79M
R&D / revenue
15.4%
Stock compensation / revenue
3.0%

Ownership (13F)

9 metrics
13F filers
28
13F filer change QoQ
+2
Institutional ownership
42.3%
Conviction holders (share of 13F filers)
3.6%
Crowding (high-turnover and private-fund holders)
34.3%
Private-fund adviser ownership
34.3%
Active holders' share change QoQ
+3.6%
Holder tenure
21.8
Price vs estimated holder cost
-2.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
2.9%

Short interest

3 metrics
Short interest
0.6%
Latest settlement · 9.4 days to cover
Days to cover
9.4d
Short-squeeze score
49 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 771856 CUSIP 15870P307 13F (30d) 3 filings 3 filers Visit website Investor relations